Who we are
Founded in 2011 by a group of science and industry experts, MaSTherCell provides unequalled quality manufacturing services to the cell therapy community. Thanks to our customer-driven approach, our expertise in cell therapy and our location in the heart of Europe, we are ideally positioned for growth in this rapidly-evolving niche market.
The key competitive advantages that MaSTherCell offers to both its customers and its partners are:
- A custom-made approach, tailored to the specific requirements of our clients, and designed to ensure short lead times and competitive costs in getting products to the market.
- An in-house expertise that is drawn from both academic and industry backgrounds. Our highly flexible staff structure combines the ideal mix between scientific and market-oriented disciplines.
- A complete range of services - our advanced Project Management Programme allows us to offer a centrally managed service that covers every step of the process 'from bench to market'.
Our mission and vision
At MaSTherCell we believe the best way to serve our customers is to combine scientific expertise and business and operational acumen to provide an unequalled manufacturing service in the cell therapy field. Put simply, our mission is to help our customers bring highly potent cell therapy products faster to the market. Our technology-driven, quality-minded and customer-oriented team of committed experts are dedicated to achieving that mission.·
Building a customer oriented culture and a quality driven organisation that will create trust amongst our customers by ensuring access to quality products for their patients.
MaSTherCell, (Manufacturing Synergies for Therapeutic Cells) was founded in 2011 as a cell therapy dedicated Contract Development and Manufacturing Organization (CDMO). From the outset, the aim of the company was to combine academic and industry excellence to provide unparalleled quality manufacturing services.
The company was set up with investment from the founders as well as from institutional investors Sambrinvest and Sofipole and other private investors, and also with the support of the Walloon Region and its Life Sciences cluster, BioWin.
Located in just 40 minutes from Brussels, the capital of Europe, MaSTherCell's state-of-the-art facilities in theI-tech Incubator Building in Gosselies are now fully operational and received the final cGMP manufacturing authorization from the BelgianDrug Agency (AFMPS) in September 2013.
MaSTherCell's considerable expertise is based on the background of its principals who, between them, combine close to 100 years of senior managerial and scientific experience in the Life Sciences sector.
Through a reversible deal, MaSTherCell has been acquired by Orgenesis (a leader in the emerging fields of cellular therapy and re-generative medicine for the treatment of Type 1 Diabetes) in March 2015. MaSTherCell will be responsible for the development and the commercialization of Orgenesis' product and will also maintain his CDMO core business activity in an independent way.
In 2017, MaSTherCell will reach more than 100 employees with a global presence in order to crystalize its position as ultimate cell therapy manufacturing partner for leading biotech companies targeting a fast and cost effective development of their product to the market.